Eli Lilly and Company (NYSE:LLY) Shares Purchased by Country Trust Bank

Country Trust Bank raised its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 9.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,283 shares of the company’s stock after buying an additional 17,963 shares during the period. Eli Lilly and makes up approximately 1.6% of Country Trust Bank’s holdings, making the stock its 14th largest holding. Country Trust Bank’s holdings in Eli Lilly and were worth $57,641,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. AllSquare Wealth Management LLC purchased a new position in Eli Lilly and in the fourth quarter valued at about $28,000. HWG Holdings LP purchased a new position in shares of Eli Lilly and during the 4th quarter worth approximately $28,000. Icapital Wealth LLC purchased a new position in shares of Eli Lilly and during the 1st quarter worth approximately $28,000. Leverty Financial Group LLC purchased a new position in shares of Eli Lilly and during the 4th quarter worth approximately $29,000. Finally, FSB Premier Wealth Management Inc. purchased a new position in shares of Eli Lilly and during the 4th quarter worth approximately $30,000. 82.75% of the stock is owned by institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 41,857 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $329.05, for a total transaction of $13,773,045.85. Following the sale, the insider now owns 104,161,953 shares in the company, valued at $34,274,490,634.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total transaction of $313,440.00. Following the sale, the chief accounting officer now owns 6,274 shares in the company, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,048,829 shares of company stock valued at $328,740,043. Company insiders own 0.12% of the company’s stock.

Several analysts have commented on LLY shares. Bank of America lifted their target price on shares of Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Mizuho lifted their target price on shares of Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $311.65.

Shares of NYSE:LLY opened at $328.30 on Wednesday. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60. Eli Lilly and Company has a fifty-two week low of $220.20 and a fifty-two week high of $330.85. The firm has a 50-day simple moving average of $303.04 and a 200 day simple moving average of $279.44. The company has a market cap of $311.94 billion, a PE ratio of 48.47, a P/E/G ratio of 2.25 and a beta of 0.37.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.30. The company had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.87 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 8.29 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be paid a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 58.07%.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.